AMG 410 + Pembrolizumab + Panitumumab
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
KRAS Altered Advanced or Metastatic Solid Tumors
Conditions
KRAS Altered Advanced or Metastatic Solid Tumors
Trial Timeline
Jul 31, 2025 → Apr 20, 2031
NCT ID
NCT07094113About AMG 410 + Pembrolizumab + Panitumumab
AMG 410 + Pembrolizumab + Panitumumab is a phase 1 stage product being developed by Amgen for KRAS Altered Advanced or Metastatic Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07094113. Target conditions include KRAS Altered Advanced or Metastatic Solid Tumors.
What happened to similar drugs?
0 of 2 similar drugs in KRAS Altered Advanced or Metastatic Solid Tumors were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07094113 | Phase 1 | Recruiting |
Competing Products
20 competing products in KRAS Altered Advanced or Metastatic Solid Tumors